2019
DOI: 10.1016/j.jval.2019.09.616
|View full text |Cite
|
Sign up to set email alerts
|

Pcn423 Measuring Fatigue Symptoms and Impacts in Chronic Lymphocytic Leukemia (Cll): Evaluating Dimensionality of the Facit-Fatigue

Abstract: 7.15 and 7.36 years, in the 18-and 30-month DBLs, respectively. Extrapolated 18-month DBL landmark survival at 5, 10, and 20 years was 39.9%, 23.0%, and 11.1%, which remained stable at the 30-month DBL as 40.7%, 23.9%, and 11.8%, all respectively. Conclusions: Nivolumab+ipilimumab is the first immunooncology combination that has shown significant and stable long-term OS benefit in 1L RCC compared with standard of care (sunitinib). The new DBLs confirm the robustness of the 18-month DBL results, including the c… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles